Pulse 10/28/2013 Planning Australia The Australian Nuclear Science & Technology Organisation is planning to build a nuclear medicine molybdenum-99 manufacturing plant. The plant will be located in Menai, about 25 miles southwest of Sydney. The plant will include special shielded cells for the processing to ensure operator safety and systems to ensure gaseous emissions are safely controlled. Molybdenum-99 is used to produce technetium-99, a medical isotope used for diagnosing heart disease, cancers, and kidney and gastrointestinal tract disorders. Merrick & Co. will serve as the consulting engineering firm. Construction is expected to start in 2014, with production scheduled to begin
The market is generally healthy and steadily growing, and margins are up for large specialty contractors. Further, advances in design tools and owner demand for collaboration are giving subcontractors a seat at the table early on in projects.